0001138978
false
0001138978
2022-07-27
2022-07-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest reported): July 27, 2022
Novo
Integrated Sciences, Inc.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
001-40089 |
|
59-3691650 |
| (State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
Incorporation) |
|
File
Number) |
|
Identification
Number) |
11120
NE 2nd Street, Suite 100, Bellevue, WA 98004
(Address
of principal executive offices)
(206)
617-9797
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2.)
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange on which Registered |
| Common
Stock, $0.001 par value |
|
NVOS |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
4.01. Changes in Registrant’s Certifying Accountant.
(a)
Resignation of Independent Registered Public Accounting Firm
On
July 27, 2022, SRCO Professional Corporation (“SRCO”) resigned as the Company’s independent registered public accounting
firm due to the rapid growth of the Company and SRCO’s resource constraints.
SRCO’s
reports on the Company’s financial statements for the fiscal years ended August 31, 2021 and 2020 did not contain an adverse opinion
or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. Furthermore, during
the Company’s two most recent fiscal years and through July 27, 2022, there have been no disagreements with SRCO on any matter
of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved
to SRCO’s satisfaction, would have caused SRCO to make reference to the subject matter of the disagreement in connection with its
reports on the Company’s financial statements for such periods.
For
the fiscal years ended August 31, 2021 and 2020 and through July 27, 2022, there were no “reportable events” as that term
is described in Item 304(a)(1)(v) of Regulation S-K.
The
Company provided SRCO with a copy of the disclosure contained herein, prior to its filing with the Securities and Exchange Commission
(the “Commission”), and requested that SRCO furnish the Company a letter addressed to the Commission stating whether or not
it agreed with the statements herein and, if not, stating the respects in which it does not agree. SRCO’s letter to the Commission
is attached hereto as Exhibit 16.1.
(b)
Engagement of New Independent Registered Public Accounting Firm
On
July 27, 2022, the Company’s Board of Directors appointed Fruci & Associates II, PLLC (“Fruci”) as the Company’s
new independent registered public accounting firm. During the Company’s two most recent fiscal years and through July 27, 2022,
neither the Company nor anyone acting on the Company’s behalf consulted Fruci with respect to any of the matters or reportable
events set forth in Item 304(a)(2)(i) and (ii) of Regulation S-K.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Novo
Integrated Sciences, Inc. |
| |
|
|
| Dated:
July 29, 2022 |
By:
|
/s/
Robert Mattacchione |
| |
|
Robert
Mattacchione |
| |
|
Chief
Executive Officer |
